To address these knowledge gaps, we leveraged both cross-sectional Aβ and CSF p-tau levels, resting-state fMRI connectomics, longitudinal tau-PET (measuring accumulation of insoluble tau aggregates) and longitudinal cognitive assessments (measuring cognitive decline) in two independent large-scale AD cohort studies. Here, MAPT is linked to Alzheimer disease.